Classifications

• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
  • A23L2/52—Adding ingredients
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
  • A23L2/52—Adding ingredients
  • A23L2/66—Proteins
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
  • A23L2/70—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/16—Inorganic salts, minerals or trace elements
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/16—Inorganic salts, minerals or trace elements
  • A23L33/165—Complexes or chelates
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/17—Amino acids, peptides or proteins
  • A23L33/18—Peptides; Protein hydrolysates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/48—Reproductive organs
  • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/08—Solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism

Definitions

• the present invention can be used in the fields of pharmaceuticals, quasi-drugs, foods, etc. with respect to beverages containing animal placenta extract.
• Animal placenta extract is an extract extracted from the placenta of mammals such as pigs, cows, horses, humans or sheep. Mammalian placenta tissue is rich in amino acids, active peptides, vitamins, minerals, sugars, enzymes, nucleic acids, etc., which are essential nutrients for fetal growth, and is an extract extracted from the mammalian placenta. Is called placenta extract (Patent Document 1). Since the animal placenta extract has a peculiar taste and odor, a masking technique when ingested as a beverage has been reported (Patent Document 2).
• An object of the present invention is to provide a beverage having a low carbohydrate content, which suppresses the formation of precipitates derived from animal placenta extract.
• the present inventors have unexpectedly found that the formation of a precipitate can be suppressed by blending an iron compound, and have completed the present invention. Further, they have found that the effect of suppressing precipitation formation is further enhanced by blending an iron compound and a collagen peptide, and have completed the present invention.
• the aspects of the present invention obtained from such findings are as follows.
• the iron compound is ferrous fumarate, ferric chloride, iron citrate, ammonium iron citrate, sodium ferrous citrate, ferrous gluconate, iron lactate, ferrous pyrophosphate, pyrrolin.
• the beverage according to (1) to (3) which is at least one selected from the group consisting of ferric acid acid, ferrous sulfate and iron hem.
• the beverage according to (2) to (6), wherein the content of collagen peptide is 0.02 to 20 w / v%.
• the beverage according to (1) to (7) which has a pH of 2.5 to 4.5.
• a method for suppressing precipitation formation which comprises blending an iron compound in a beverage containing animal placenta extract.
• a method for suppressing precipitation formation which comprises an iron compound and a collagen peptide in a beverage containing animal placenta extract. Is.
• the animal placenta which is the raw material of the animal placenta extract used in the present invention, is not particularly limited, and is, for example, an edible placenta obtained as a postpartum at the time of full-term delivery of a healthy animal properly bred on a farm, such as the uterus. It is a marine placenta-like substance that does not contain external organs or is contained in the placenta of fish and the like.
• the origin thereof is not particularly limited, and examples thereof include humans, cows, pigs, horses, sheep, and salmon, but pigs, horses, and salmon are preferable, and pigs are more preferable.
• the form of the animal placenta extract is not particularly limited, and is, for example, a liquid or paste obtained through an extraction step after being decomposed by a method such as enzymatic decomposition or hydrochloric acid decomposition, and may be freeze-dried or spray-dried. , It may be in the form of a powder from which water has been removed.
• animal placenta extract of the present invention a commercially available product may be used, for example, "Pig Placenta Extract AL-20” (manufactured by Sankyo Biochemicals Co., Ltd.) and "Horse Placenta Extract AL-20” (Sankyo Bio Co., Ltd.).
• the content of the animal placenta extract of the present invention is preferably 0.001 to 4 w / v%, more preferably 0.01 to 2 w / v%, and further preferably 0.02 to 2 w / v% in the beverage of the present invention.
• the placenta-equivalent amount is preferably 0.025 to 100 w / v%, more preferably 0.25 to 50 w / v%.
• the "placenta-equivalent amount" is the amount of placenta required to obtain the placenta extract.
• the content of the placenta extract is preferably 0.005 to 20000 parts by mass, more preferably 0.025 to 2000 parts by mass with respect to 1 part by mass of iron in terms of iron compound (iron equivalent) described later. It is preferable, 0.5 to 1000 parts by mass is more preferable, and 10 to 200 parts by mass is particularly preferable. In terms of placenta, 0.125 to 500,000 parts by mass is preferable, 0.625 to 50,000 parts by mass is more preferable, and 12.5 to 25,000 parts by mass is most preferable with respect to 1 part by mass of the iron compound (iron equivalent).
• the "iron compound” may be either a divalent iron compound or a trivalent iron compound, for example, ferrous fumarate, ferric chloride, iron citrate, ammonium iron citrate, or ferrous citrate.
• a divalent iron compound for example, ferrous fumarate, ferric chloride, iron citrate, ammonium iron citrate, or ferrous citrate.
• examples thereof include sodium monoferric acid, ferrous gluconate, iron lactate, ferrous pyrophosphate, ferric pyrophosphate, ferrous sulfate and hem iron.
• trivalent iron compounds such as ferric chloride, iron citrate, ammonium iron citrate and ferric pyrophosphate are preferable.
• the content of the iron compound in the beverage of the present invention is preferably 0.0002 to 0.2 w / v%, more preferably 0.001 to 0.1 w / v%, and 0.002 to 0.04 w in terms of iron. / V% is more preferred.
• the iron compound is preferably 0.001 to 2.0 w / v%, more preferably 0.005 to 1.2 w / v%, and even more preferably 0.01 to 0.5 w / v%.
• the iron compound content in the beverage of the present invention preferably has an upper limit of 0.2 w / v%, more preferably 0.1 w / v%, and 0.04 w / v in terms of iron. v% is most preferable.
• the content of the iron compound in the beverage of the present invention is preferably 1 mg to 20 mg in terms of iron per oral intake.
• the single oral intake is the amount by which the beverage of the present invention is orally ingested at one time, for example, 30 to 200 ml, typically 30 ml, 50 ml, 100 ml, 150 ml, 200 ml.
• the amount is, for example, 15 to 200 g, typically 15 g, 30 g, 50 g, 100 g, 150 g, 150 g, 200 g.
• the form of the oral liquid container or the beverage container is not particularly limited.
• the capacity of the container is not particularly limited, but can be, for example, 30 ml to 200 ml (typically 50 ml, 100 ml, 150 ml, or 200 ml).
• the beverage of the present invention has a carbohydrate content of 0 to 40 w / v%, more preferably 0 to 20 w / v%, still more preferably 0 to 15% w / v%, and particularly preferably 0 to 0 to. It is 10 w / v%.
• Carbohydrates include sugar, high fructose corn syrup, fructose, fructose-fructose syrup, fructose-fructose syrup, honey, starch syrup, powdered starch syrup, maltodextrin, sorbitol, martitol, reduced starch syrup, maltose, trehalose, brown sugar, etc. Examples thereof include organic acids such as citric acid and fructose.
• the calorie of the beverage of the present invention is preferably 0 to 150 kcal / 100 ml, more preferably 0 to 100 kcal / 100 ml, and even more preferably 0 to 70 kcal / 100 ml.
• the origin of the "collagen peptide” is not particularly limited and may be synthetic, and the skin, bone, ligament, tendon, and cartilage produced as a by-product when processing livestock such as cows and pigs and fish It may be a collagen peptide produced by extracting from the above, but a collagen peptide derived from pig and fish is preferable.
• a collagen peptide obtained by decomposing collagen protein by enzyme, chemical treatment or the like is preferable.
• the average molecular weight of the collagen peptide is not particularly limited, but is preferably 500 to 50,000, and more preferably 1,000 to 25,000.
• collagen peptide of the present invention a commercially available product may be used, for example, "Nippi Peptide PS-1” (registered trademark, manufactured by Nippi Co., Ltd.), “Nippi Peptide PRA-P” (registered trademark, manufactured by Nippi Co., Ltd.).
• the content of collagen peptide is preferably 0.02 to 20 w / v%, more preferably 0.1 to 15 w / v%, still more preferably 0.2 to 15 w / v% in the beverage of the present invention. ..
• the content of collagen peptide is preferably 0.1 to 100,000 parts by mass, more preferably 0.5 to 10,000 parts by mass, based on 1 part by mass of iron in terms of iron compound (iron equivalent). It is more preferably 7500 parts by mass, and particularly preferably 20 to 7500 parts by mass. Further, 0.005 to 20000 parts by mass is preferable, 0.01 to 1000 parts by mass is more preferable, 0.1 to 750 parts by mass is further preferable, and 0.5 to 150 parts by mass is preferable with respect to 1 part by mass of placenta extract. Especially preferable.
• placenta extract When the placenta extract is converted into a placenta, 0.0002 to 800 parts by mass is preferable, 0.002 to 40 parts by mass is more preferable, 0.004 to 30 parts by mass is more preferable, and 0 is 0 parts by mass of the placenta. .02 to 6 parts by mass is particularly preferable.
• the present invention can suppress the formation of a precipitate derived from animal placenta extract by blending an iron compound. Further, when collagen peptide is further added, the effect of suppressing the formation of the precipitate derived from the animal placenta extract is enhanced.
• the animal placenta is not particularly limited, but when the formation of the precipitate is suppressed only by the iron compound, the pig-derived animal placenta is particularly preferable.
• the beverage in the present invention is not particularly limited as long as it is a liquid that can be orally ingested, and is a drug, a non-medicinal product, or a food (not only general foods, but also nutritionally functional foods, foods for specified health uses, and foods with functional claims). Also included).
• Examples of pharmaceuticals and quasi-drugs include internal liquids and drinks. Examples of foods include soft drinks, carbonated drinks, sports / functional drinks, non-alcoholic drinks, dairy drinks, tea drinks, coffee drinks, fruit / vegetable drinks, jelly drinks and the like. More preferably, it is an internal liquid or drink for pharmaceuticals and quasi-drugs, and various beverages such as nutritional functional foods and foods for specified health use, carbonated beverages and jelly beverages for foods.
• the pH of the beverage of the present invention is not particularly limited, but is preferably 2.5 to 4.5, more preferably 3.0 to 4.0, from the viewpoint of good mouthfeel.
• a pH adjuster such as an organic acid can be added as needed.
• the beverage of the present invention can be produced by a conventional method, and the method is not particularly limited. Usually, it is obtained by weighing each component, dissolving and stirring with an appropriate amount of purified water, adjusting the pH, further adding purified water to adjust the volume, and performing filtration and sterilization treatment as necessary.
• the beverage of the present invention as other components, vitamins, minerals, amino acids and salts thereof, crude drugs, crude drug extracts, caffeine, royal jelly, dextrin and the like are appropriately added as long as the effects of the present invention are not impaired. Can be blended. Further, if necessary, additives such as antioxidants, colorants, flavors, flavoring agents, preservatives, sweeteners, and acidulants can be appropriately blended as long as the effects of the present invention are not impaired.
• Beverages with the formulations listed in Table 1 below were prepared according to the following method. First, citric acid (citric acid monohydrate) and sodium benzoate were dissolved in purified water, and the volume was adjusted to 60 v / v% of the total amount to obtain an acidulant solution. Next, ammonium iron citrate was dissolved in purified water and the volume was adjusted so as to contain 0.2 to 0.4 w / v% as iron to obtain an iron solution. To the acidulant solution, add an iron solution or iron compound and pig-derived animal placenta extract (P-placenta extract manufactured by Nippon Ham Co., Ltd.) as necessary so that the formulation shown in the table is obtained, and the total amount is 90v /.
• P-placenta extract manufactured by Nippon Ham Co., Ltd. pig-derived animal placenta extract manufactured by Nippon Ham Co., Ltd.
• Examples 1-1 to 4-1 Purified water was added so as to be about v%, and the mixture was sufficiently stirred. After sufficient stirring, the pH was adjusted with hydrochloric acid or sodium hydroxide, and purified water was added to make the total amount to obtain a beverage (Examples 1-1 to 4-1). These beverages are referred to as screw tube No. 7 (manufactured by Maruemu Co., Ltd.) was filled with 50 ml and sterilized at 80 ° C. for 25 minutes. Beverages to which ammonium ferric citrate was not added (Comparative Examples 1 to 4) were used as controls. The beverage prepared as described above was stored at 65 ° C. for 7 days, and the precipitate was visually observed. The degree of precipitation formation was evaluated according to the criteria shown in Table 2.
• Example 1-1 for Comparative Example 1, Examples 2-1 to 2-3 for Comparative Example 2, and Examples 3-1 to 3-5 for Comparative Example 3-1.
• Example 4-1 precipitation formation was suppressed by blending the iron compound.
• the beverages of the formulations shown in Tables 3 and 4 below were prepared according to the following methods. First, citric acid (citric acid monohydrate) and sodium benzoate were dissolved in purified water, and the volume was adjusted to 60 v / v% of the total amount with purified water to obtain an acidulant solution. Next, ammonium iron citrate was dissolved in purified water, and the volume was adjusted so as to contain 0.2 to 0.4 w / v% as iron to obtain an iron solution. If necessary, add an iron solution or an iron compound to the acidulant solution so as to be as shown in the table, and add pig-derived animal placenta extract (P-placenta extract manufactured by Nippon Ham Co., Ltd.) and collagen peptide.
• P-placenta extract manufactured by Nippon Ham Co., Ltd.
• Example 42 Collagen peptide derived from pigs (molecular weight about 5000) is Korapep JB (registered trademark, manufactured by Nitta Gelatin Co., Ltd.), and collagen peptide derived from pigs (molecular weight about 4000-12000) is Nippi Peptide PRA-P (registered trademark, manufactured by Nitta Gelatin Co., Ltd.).
• Nippi Peptide FCP-EX (registered trademark, manufactured by Nippi Co., Ltd.) was used as the collagen peptide derived from fish (manufactured by Nippi) and fish-derived collagen peptide (molecular weight of about 4000). These beverages are referred to as screw tube No. 7 (manufactured by Maruemu Co., Ltd.) was filled with 50 ml and sterilized at 80 ° C. for 25 minutes. Beverages to which ammonium iron citrate and collagen peptide were not added (Comparative Examples 1 to 4) were used as controls. The beverage prepared as described above was stored at 65 ° C. for 7 days, and the precipitate was visually observed. The degree of precipitation formation was evaluated according to the criteria shown in Table 2.
• Beverages with the formulations listed in Table 5 below were prepared according to the following method. First, citric acid (citric acid monohydrate) and sodium benzoate were dissolved in purified water, and the volume was adjusted with purified water having a total amount of about 60 v / v% to obtain an acidulant solution. Next, sodium ferrous citrate, pig-derived animal placenta extract (P-placenta extract manufactured by Nippon Ham Co., Ltd.) and collagen peptide are added in order, and purified water is added so that the total amount is about 90 v / v%. , Stirred well.
• citric acid citric acid monohydrate
• sodium benzoate sodium benzoate
• Example 3-14 a beverage
• These beverages are referred to as screw tube No. 7 (manufactured by Maruemu Co., Ltd.) was filled with 50 ml and sterilized at 80 ° C. for 25 minutes.
• the beverage prepared as described above was stored at 65 ° C. for 7 days, and the precipitate was visually observed. The degree of precipitation formation was evaluated according to the criteria shown in Table 2.
• a beverage to which sodium ferrous citrate and collagen peptide were not added (Comparative Example 3-1) was used as a control.
• Beverages with the formulations listed in Table 6 below were prepared according to the following method. First, citric acid (citric acid monohydrate) and sodium benzoate were dissolved in purified water, and the volume was adjusted to 60 v / v% of the total amount with purified water to obtain an acidulant solution. Next, ammonium iron citrate was dissolved in purified water, and the volume was adjusted so as to contain 0.4 w / v% as iron to obtain an iron solution. Add an iron solution to the acidulant solution according to the formulation shown in the table, and add salmon-derived placenta extract (Japan Barrier Free Marine Placenta (MP)) or horse-derived placenta extract (Dard Co., Ltd. horse).
• MP Job Barrier Free Marine Placenta
• the melon placenta-derived plant placenta extract was blended to obtain a beverage by the same method as the preparation in Table 1 or Table 3 (Comparative Examples 7-1 to 8-). 2).
• These beverages are referred to as screw tube No. 7 (manufactured by Maruemu Co., Ltd.) was filled with 50 ml and sterilized at 80 ° C. for 25 minutes.
• the beverage prepared as described above was stored at 65 ° C. for 7 days, and the precipitate was visually observed. The degree of precipitation formation was evaluated according to the criteria shown in Table 2. Beverages to which ammonium iron citrate and collagen peptide were not added (Comparative Examples 7-1 and 8-1) were used as controls.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Polymers & Plastics (AREA)
• Food Science & Technology (AREA)
• Nutrition Science (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Mycology (AREA)
• Inorganic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Developmental Biology & Embryology (AREA)
• Cell Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Molecular Biology (AREA)
• Pregnancy & Childbirth (AREA)
• Reproductive Health (AREA)
• Biomedical Technology (AREA)
• Biotechnology (AREA)
• Immunology (AREA)
• Virology (AREA)
• Zoology (AREA)
• Organic Chemistry (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Non-Alcoholic Beverages (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Publications (1)

Family

ID=81708827

Family Applications (1)

Country Status (2)

Citations (3)

• 2021
  • 2021-11-11 JP JP2021576325A patent/JP7112040B1/ja active Active
  • 2021-11-11 WO PCT/JP2021/041452 patent/WO2022107673A1/ja not_active Ceased
• 2022
  • 2022-01-21 JP JP2022008167A patent/JP2022081472A/ja active Pending

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events